| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Schwerpunkt Endokrinologie, Abt. Innere Medizin II, Klinikum der Albert-Ludwigs-Universität Freiburg (F.B., P.M. M.R.); Schwerpunkt Endokrinologie, Medizinische Universitätsklinik Würzburg (F.B., B.A.); and Institut für Pharmakologie, Universität Heidelberg (E.S., H.-P.G., C.M.-G.), Heidelberg, Germany
Address all correspondence and requests for reprints to: M. Reincke Abt. Innere Medizin II, Klinikum der Universität, Hugstetter Strasse 55 79106 Freiburg, Germany. E-mail: reincke{at}mm21.ukl.uni-freiburg.de
Twenty-one hydroxylase (P450c21) is a key enzyme essential for normal
zona glomerulosa and fasciculata function. Recently,
21-hydroxylase deficiency has been implicated in the
pathogenesis of adrenocortical tumors. Therefore, we investigated the
mutational spectrum of the CYP21B gene and the messenger RNA expression
of P450c21 in six aldosterone-producing adenomas, seven
cortisol-producing adenomas, two nonfunctional incidentally detected
adenomas, and four adrenal carcinomas. DNA from leukocytes and tumors
was amplified by PCR using primers specific for the CYP21B gene. The 10
exons, intron 2, intron 7, all other exon/intron junctions, and 380 bp
of the promoter region of CYP21B were automatically sequenced. Poly(A)
RNA was extracted from tumor tissue, dot blotted on a nylon membrane,
and hybridized with 32P-labeled P450 side-chain cleavage,
P450 17-
-hydroxylase, and P450c21 complementary DNA probes. We
detected heterozygous germline mutations (exon 7, Val 281Leu) in two
patients, one with a cortisol-producing adenoma and the other with an
androgen-secreting adrenocortical carcinoma. A somatic, heterozygous
microdeletion was found in exon 3 of one aldosterone-producing adenoma.
The P450c21 gene expression correlated with the clinical phenotype of
the tumor, with low P450c21 messenger RNA expression in nonfunctional
adenomas (18.8%, 1.5%) compared with high P450c21 expression in
aldosterone- and cortisol-producing adenomas (84 ± 8% and
101 ± 4%, respectively, vs. normal adrenals,
100 ± 10%). In conclusion, the prevalence of heterozygous
germline mutations in the CYP21B gene was higher in patients with
adrenocortical tumors (11%; 95% confidence interval, 134%) than in
the general European population (2%; 95% confidence interval,
1.932.06%), but this difference is questionable because of the low
number of subjects in our series. The pathophysiological significance
of this finding in the presence of one normal CYP21B gene seems to be
low, suggesting that 21-hydroxylase deficiency is not a major
predisposing factor for adrenal tumor formation.
This article has been cited by other articles:
![]() |
M. Janner, A. V Pandey, P. E Mullis, and C. E Fluck Clinical and biochemical description of a novel CYP21A2 gene mutation 962_963insA using a new 3D model for the P450c21 protein. Eur. J. Endocrinol., July 1, 2006; 155(1): 143 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Assie, C. Auzan, J.-M. Gasc, E. Baviera, A. Balaton, J.-M. Elalouf, X. Jeunemaitre, P.-F. Plouin, P. Corvol, and E. Clauser Steroidogenesis in Aldosterone-Producing Adenoma Revisited by Transcriptome Analysis J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6638 - 6649. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Libe and J. Bertherat Molecular genetics of adrenocortical tumours, from familial to sporadic diseases Eur. J. Endocrinol., October 1, 2005; 153(4): 477 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Grigorescu Sido, M. M. Weber, P. Grigorescu Sido, S. Clausmeyer, U. Heinrich, and E. Schulze 21-Hydroxylase and 11{beta}-Hydroxylase Mutations in Romanian Patients with Classic Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5769 - 5773. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ortmann, J. Hausmann, F. Beuschlein, K. Schmenger, M. Stahl, M. Geissler, and M. Reincke Steroidogenic Acute Regulatory (StAR)-Directed Immunotherapy Protects against Tumor Growth of StAR-Expressing Sp2-0 Cells in a Rodent Adrenocortical Carcinoma Model Endocrinology, April 1, 2004; 145(4): 1760 - 1766. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Mancini, B. Kola, F. Mantero, and G. Arnaldi Functional and Nonfunctional Adrenocortical Tumors Demonstrate a High Responsiveness to Low-Dose Adrenocorticotropin J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1994 - 1998. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Koch, K. Pacak, and G. P. Chrousos The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5367 - 5384. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Baumgartner-Parzer, E. Schulze, W. Waldhausl, S. Pauschenwein, S. Rondot, P. Nowotny, K. Meyer, H. Frisch, F. Waldhauser, and H. Vierhapper Mutational Spectrum of the Steroid 21-Hydroxylase Gene in Austria: Identification of a Novel Missense Mutation J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4771 - 4775. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. White and P. W. Speiser Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Endocr. Rev., June 1, 2000; 21(3): 245 - 291. [Abstract] [Full Text] |
||||
![]() |
Y. Takeda, K. Furukawa, S. Inaba, I. Miyamori, and H. Mabuchi Genetic Analysis of Aldosterone Synthase in Patients with Idiopathic Hyperaldosteronism J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1633 - 1637. [Abstract] [Full Text] |
||||
![]() |
M. Kjellman, L. Roshani, B. T. Teh, O.-P. Kallioniemi, A. Höög, S. Gray, L.-O. Farnebo, M. Holst, M. Bäckdahl, and C. Larsson Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16 J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 730 - 735. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |